Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-arm, Open-label, Non-interventional, Multicenter to Assess the Safety of BNT162b2 in Domestic Post-marketing Surveillance

NCT05032976 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05032976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05032976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-arm, Open-label, Non-interventional, Multicenter to Assess the Safety of BNT162b2 in Domestic Post-marketing Surveillance
Lead sponsor
Pfizer
Phase
Observational
Overall status
Active, not recruiting
Start date
March 18, 2022
Completion date
January 24, 2027
Enrollment
12,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse effects, covid-19, safety, sars-cov-2, vaccines